- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- Obesity drug beloranib shows promise in Prader-Willi population in Phase 2 trials
- EXPERT BLOG: Provider status for pharmacists — one way or another
PHILADELPHIA — The Food and Drug Administration has approved a drug for managing obesity made by Lannett.
Lannett announced the approval of phentermine hydrochloride capsules in the 37.5-mg strength, a generic version of Teva’s Adipex-P.
Phentermine hydrochloride capsules in the 37.5-mg strength had sales of about $8.8 million during the 12-month period ended in May, according to Wolters Kluwer.